Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1528-3658
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics ; volume:24 ; number:1 ; day:24 ; month:9 ; year:2018 ; pages:1-15 ; date:12.2018
Molecular medicine ; 24, Heft 1 (24.9.2018), 1-15, 12.2018
- Urheber
-
Runcie, Karie
- Beteiligte Personen und Organisationen
-
Budman, Daniel R.
John, Veena
Seetharamu, Nagashree
SpringerLink (Online service)
- DOI
-
10.1186/s10020-018-0051-4
- URN
-
urn:nbn:de:101:1-2018110722032404404237
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek.
Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Runcie, Karie
- Budman, Daniel R.
- John, Veena
- Seetharamu, Nagashree
- SpringerLink (Online service)
Ähnliche Objekte (12)
Bi-specific Aptamers mediating Tumour Cell Lysis
Developing novel specific therapeutics targeting adipocytes
Immunogenicity Risk Assessment for Multi-specific Therapeutics
Cell-type specific potent Wnt signaling blockade by bispecific antibody
Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy
Design and Evaluation of Tumor‐Specific Dendrimer Epigenetic Therapeutics
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Structural insights into the bi-specific cross-over dual variable antibody architecture by cryo-EM
Targeting the Tie2–αvβ3 integrin axis with bi-specific reagents for the inhibition of angiogenesis
A bi-specific lectin from the mushroom Boletopsis grisea and its application in glycoanalytical workflows
Bi-specific Aptamers mediating Tumour Cell Lysis
Developing novel specific therapeutics targeting adipocytes
Immunogenicity Risk Assessment for Multi-specific Therapeutics
Cell-type specific potent Wnt signaling blockade by bispecific antibody
Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy
Design and Evaluation of Tumor‐Specific Dendrimer Epigenetic Therapeutics
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Structural insights into the bi-specific cross-over dual variable antibody architecture by cryo-EM
Targeting the Tie2–αvβ3 integrin axis with bi-specific reagents for the inhibition of angiogenesis
A bi-specific lectin from the mushroom Boletopsis grisea and its application in glycoanalytical workflows
Bi-specific Aptamers mediating Tumour Cell Lysis
Developing novel specific therapeutics targeting adipocytes
Immunogenicity Risk Assessment for Multi-specific Therapeutics
Cell-type specific potent Wnt signaling blockade by bispecific antibody
Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy
Design and Evaluation of Tumor‐Specific Dendrimer Epigenetic Therapeutics
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Structural insights into the bi-specific cross-over dual variable antibody architecture by cryo-EM
Targeting the Tie2–αvβ3 integrin axis with bi-specific reagents for the inhibition of angiogenesis